Sean Bohen (file photo)
November 1, 2020 03:08 PM ESTUpdated November 3, 11:07 AM
People
Financing
Bioregnum
Opinion

Sean Bo­hen just wrote the hand­book on how to make a quick for­tune in biotech

If you ask any­one in drug de­vel­op­ment about what mo­ti­vates them — or even if you don’t — you’re go­ing to get a reg­u­lar dou­ble-bar­reled blast about …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

A service from the Financial Times